Zydus receives tentative approval from the USFDA for Gabapentin tablets
Zydus Lifesciences Limited’s subsidiary, Zydus Pharmaceuticals (USA) Inc., has received tentative approval from the United States Food and Drug Administration (USFDA) for Gabapentin Tablets, the company said via an exchange filing. The recommended daily dose is 300 mg or 600 mg (Gralise Tablets). Gabapentin tablets are indicated for the management of Postherpetic Neuralgia (PHN).
Source: freepressjournal.in